Global Journal of Transfusion Medicine

CASE REPORT
Year
: 2019  |  Volume : 4  |  Issue : 2  |  Page : 240--242

Interference of daratumumab with compatibility testing in blood bank


Rani Premkumar, Siva Deepthi 
 Department of Transfusion Medicine, Sakra World Hospital, Bengaluru, Karnataka, India

Correspondence Address:
Dr. Siva Deepthi
Department of Transfusion Medicine, Sakra World Hospital, Bengaluru, Karnataka
India

Plasma cell myeloma accounts for 1% of malignant tumors and 10%–15% of hematopoietic neoplasms. Daratumumab (DARA), a novel targeted immunotherapy drug, was approved by the Food and Drug Administration to treat relapsed/refractory multiple myeloma. DARA, which is a CD38-targeted immunomodulatory drug, also cross-reacts with red cells and sensitizes them, causing difficulties and delay in the blood bank. To avoid delay in view of patient care, proper communication with blood bank professionals is required. We present a case of relapsed/refractory multiple myeloma in a 45-year-old male who required transfusions due to anemia and severe thrombocytopenia.


How to cite this article:
Premkumar R, Deepthi S. Interference of daratumumab with compatibility testing in blood bank.Glob J Transfus Med 2019;4:240-242


How to cite this URL:
Premkumar R, Deepthi S. Interference of daratumumab with compatibility testing in blood bank. Glob J Transfus Med [serial online] 2019 [cited 2020 May 25 ];4:240-242
Available from: http://www.gjtmonline.com/article.asp?issn=2468-8398;year=2019;volume=4;issue=2;spage=240;epage=242;aulast=Premkumar;type=0